Trials / Unknown
UnknownNCT03435094
Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes
A Non-interventional Two-arm Two-centre, Retrospective/Prospective Study to Compare the Effect of Alendronate 70mg Formulation (Tablet vs Effervescent Tablet) on Bone Turnover Markers and Patient Reported Outcomes
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Labatec Pharma SA · Industry
- Sex
- Female
- Age
- 55 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Compare the data obtained with two formulations of alendronate 70 mg (tablets vs effervescent tablet for buffered solution) on the change in bone turnover markers, on gastric tolerance and on treatment adherence (including compliance and persistence).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Binosto 70Mg Effervescent Tablet | Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes. |
| DRUG | Fosamax 70Mg Tablet | Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes. |
Timeline
- Start date
- 2018-02-25
- Primary completion
- 2022-03-31
- Completion
- 2022-12-01
- First posted
- 2018-02-15
- Last updated
- 2020-12-03
Locations
2 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT03435094. Inclusion in this directory is not an endorsement.